PATENT APPLICATION

Group Art Unit:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Katherine MOLNAR-KIMBER et

Appln. No.: 09/576,951

Filed: May 24, 2000 Examiner: Ponnaluri, P.

For: ANTI-RAPAMYCIN MONOCLONAL ANTIBODIES

PRELIMINARY RESPONSE

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

Prior to examining the above-identified application, please consider the following.

REMARKS

In paragraph 29, on page 16 of the Office Action dated November 24, 1999, in Parent Application Serial No. 08/424,983, the Examiner rejected the claims under 35 U.S.C. § 103 as being unpatentable over WO 92/05179 (Caufield et al) in view of U.S. Patent 5,532,137 (Niwa et al).

Specifically, the Examiner stated that Caufield et al discloses that rapamycin is an antibiotic, as well as position 42 esters thereof. The Examiner noted that the claims of said Parent Application differ from Caufield et al in that said claims recited monoclonal antibodies specific to rapamycin. However, the Examiner contended that Niwa et al teaches methods to produce monoclonal antibodies to FR-900506, where the antibodies are

.618 P. P.C.

NOV 15 2000 TECH CENTER 1600200